Drug Approval | January 28, 2022
European Commission approves Merck’s KEYTRUDA as adjuvant therapy for RCC
KEYTRUDA is now approved as monotherapy for adults with Renal Cell Carcinoma (RCC)
KEYTRUDA is now approved as monotherapy for adults with Renal Cell Carcinoma (RCC)
According to IQVIA sales data for the 12-month period ending November 2021, the Ziac tablets, 2.5 mg/6.25 mg, 5 mg/6.25 mg, and 10 mg/6.25 mg market achieved annual sales of approximately US $ 30.3 million
Antibiotics mixed in wastewater often get disposed of into the water bodies resulting in wider antimicrobial resistance cases
Leading brands like Sporlac, Lobun, Oxalo, Pubergen, Nano-leo and Gynogen will now be part of the JBCPL franchise
Cipla announced its unaudited consolidated financial results for quarter ended December 31st, 2021.
Optimized for pharma/biopharma to deliver a deeper understanding of cellular function
The FDA grants ODD status to medicines and potential new medicines intended for the treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the US
Previously, the use of the drug was limited to patients requiring hospitalization
UCB plans to submit regulatory applications in Q3 2022
Biocon has reported consolidated financial results for the period ended December 31, 2021
Subscribe To Our Newsletter & Stay Updated
